Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial
Background Rivoceranib is an oral, selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2. ANGEL (NCT03042611) was a global, randomized, double-blinded, placebo-controlled, phase 3 study evaluating rivoceranib as 3rd-line or ≥4th-line therapy in patients with advanced/metastatic gastric or gastroesophageal junction (GEJ) cancer. Methods Patients had failed ≥2 lines of chemotherapy and were randomized 2:1 to rivoceranib 700 mg once daily or placebo with best supportive care. Primary endpoint: overall survival (OS) in the intention-to-treat population. Secondary endpoints: progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) by blinded independent central review (BICR). Results In total, 460 patients (rivoceranib n = 308, placebo n = 152) were enrolled. OS was not statistically different for rivoceranib versus placebo (median 5.78 vs. 5.13 months; hazard ratio [HR] 0.93, 95% CI 0.74–1.15; p = 0.4724). PFS by BICR (median 2.83 vs. 1.77 months; HR 0.58, 95% CI 0.47–0.71; p < 0.0001), ORR (6.5% vs. 1.3%; p = 0.0119), and DCR (40.3 vs. 13.2%; p < 0.0001) were improved with rivoceranib versus placebo. In patients receiving ≥4th-line therapy, OS (median 6.34 vs. 4.73 months; p = 0.0192) and PFS by BICR (median 3.52 vs. 1.71 months; p < 0.0001) were improved with rivoceranib versus placebo. The most common grade ≥ 3 treatment-emergent adverse events with rivoceranib were hypertension (17.9%), anemia (10.4%), aspartate aminotransferase increased (9.4%), asthenia (8.5%), and proteinuria (7.5%). Conclusions This study did not meet its primary OS endpoint. Compared to placebo, rivoceranib improved PFS, ORR, and DCR. Rivoceranib also improved OS in a prespecified patient subgroup receiving ≥4th-line therapy..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Gastric Cancer - 27(2024), 2 vom: 28. Jan., Seite 375-386 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kang, Yoon-Koo [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Stomach neoplasms |
|---|
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1007/s10120-023-01455-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054899516 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054899516 | ||
| 003 | DE-627 | ||
| 005 | 20240227064720.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10120-023-01455-5 |2 doi | |
| 035 | |a (DE-627)SPR054899516 | ||
| 035 | |a (SPR)s10120-023-01455-5-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kang, Yoon-Koo |e verfasserin |0 (orcid)0000-0003-0783-6583 |4 aut | |
| 245 | 1 | 0 | |a Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Background Rivoceranib is an oral, selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2. ANGEL (NCT03042611) was a global, randomized, double-blinded, placebo-controlled, phase 3 study evaluating rivoceranib as 3rd-line or ≥4th-line therapy in patients with advanced/metastatic gastric or gastroesophageal junction (GEJ) cancer. Methods Patients had failed ≥2 lines of chemotherapy and were randomized 2:1 to rivoceranib 700 mg once daily or placebo with best supportive care. Primary endpoint: overall survival (OS) in the intention-to-treat population. Secondary endpoints: progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) by blinded independent central review (BICR). Results In total, 460 patients (rivoceranib n = 308, placebo n = 152) were enrolled. OS was not statistically different for rivoceranib versus placebo (median 5.78 vs. 5.13 months; hazard ratio [HR] 0.93, 95% CI 0.74–1.15; p = 0.4724). PFS by BICR (median 2.83 vs. 1.77 months; HR 0.58, 95% CI 0.47–0.71; p < 0.0001), ORR (6.5% vs. 1.3%; p = 0.0119), and DCR (40.3 vs. 13.2%; p < 0.0001) were improved with rivoceranib versus placebo. In patients receiving ≥4th-line therapy, OS (median 6.34 vs. 4.73 months; p = 0.0192) and PFS by BICR (median 3.52 vs. 1.71 months; p < 0.0001) were improved with rivoceranib versus placebo. The most common grade ≥ 3 treatment-emergent adverse events with rivoceranib were hypertension (17.9%), anemia (10.4%), aspartate aminotransferase increased (9.4%), asthenia (8.5%), and proteinuria (7.5%). Conclusions This study did not meet its primary OS endpoint. Compared to placebo, rivoceranib improved PFS, ORR, and DCR. Rivoceranib also improved OS in a prespecified patient subgroup receiving ≥4th-line therapy. | ||
| 650 | 4 | |a Stomach neoplasms |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Tyrosine protein kinase inhibitors |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Vascular endothelial growth factor receptor-2 |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Ryu, Min-Hee |4 aut | |
| 700 | 1 | |a Di Bartolomeo, Maria |4 aut | |
| 700 | 1 | |a Chau, Ian |4 aut | |
| 700 | 1 | |a Yoon, Harry |4 aut | |
| 700 | 1 | |a Kim, Jong Gwang |4 aut | |
| 700 | 1 | |a Lee, Keun-Wook |4 aut | |
| 700 | 1 | |a Oh, Sang Chul |4 aut | |
| 700 | 1 | |a Takashima, Atsuo |4 aut | |
| 700 | 1 | |a Kryzhanivska, Anna |4 aut | |
| 700 | 1 | |a Chao, Yee |4 aut | |
| 700 | 1 | |a Evesque, Ludovic |4 aut | |
| 700 | 1 | |a Schenker, Michael |4 aut | |
| 700 | 1 | |a McGinn, Arlo |4 aut | |
| 700 | 1 | |a Zhao, Yufan |4 aut | |
| 700 | 1 | |a Lee, Jennifer |4 aut | |
| 700 | 1 | |a Wyrwicz, Lucjan |4 aut | |
| 700 | 1 | |a Boku, Narikazu |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gastric Cancer |d Springer-Verlag, 2002 |g 27(2024), 2 vom: 28. Jan., Seite 375-386 |w (DE-627)SPR009286586 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2024 |g number:2 |g day:28 |g month:01 |g pages:375-386 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10120-023-01455-5 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2024 |e 2 |b 28 |c 01 |h 375-386 | ||